Nanosphere Sees Q2 Revenues Rise 38 Percent; Stock Tumbles on Lowered Forecast | GenomeWeb

NEW YORK (GenomeWeb News) – Nanosphere said today that its second quarter revenues jumped 38 percent year over year, with the rise being driven by sales of its Verigene Gram-Positive Blood Culture Test.

Nanosphere also lowered its revenue guidance for the year as well as its expectations for instrument placements. In response, its shares plummeted around 32 percent to $2.00 in Wednesday morning trade on the Nasdaq.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

CBC Marketplace commissions DNA testing of chicken sandwiches at Subway and other fast-food chains.

In a speech to Congress, President Donald Trump called the drug approval process at FDA "slow and burdensome."

In Genome Research this week: algorithm to tease out strains from metagenomic sequences, drug resistance mechanisms in cancer cells, and more.

Variants in the IFITM3 gene affect inflammatory response to infection, UPI reports.